European Commission Approves Darzalex for Multiple Myeloma
News
The European Commission (EC) has conditionally approved, under accelerated assessment, Darzalex (daratumumab) for monotherapy of adults with relapsed or refractory multiple myeloma (MM), whose previous therapy included a proteasome inhibitor and an ... Read more